Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
22 results loaded, newest first. End of these results.
Eli Lilly's experimental combination drug EloraTZP led to an average body weight loss of 23.3% over 48 weeks in a mid-stage trial, compared to 14.8% for its blockbuster Zepbound alone. The company plans to start late-stage trials for EloraTZP in the fourth quarter of 2026.
Novo Nordisk reported that investigational CagriSema reduced body weight by 22.4% vs placebo at 52 weeks in an fMRI study and showed ectopic fat reductions in a diabetes sub-study, with additional bone marker findings in REIMAGINE 2.Material DetailsContext by AI AnalystThis is mid-to-late cycle cli…
Novo Nordisk said real-world analysis at EASD found Ozempic (semaglutide) 2 mg was linked to a 6% lower risk of major cardiovascular events versus switching to Mounjaro (tirzepatide).
Novo Nordisk A/S OMXCOP:NOVO_B
Novo Nordisk A/S Sponsored ADR Class B (OMXCOP:NOVO_B) is executing a cost—cutting, multi—blockbuster push—10x oral GLP—1 capacity, CagriSema launch and Wegovy expansion—while investors fret over semaglutide patent cliffs, competitive trial setbacks and an 18% YTD selloff.Previous Week RecapThis is…
By Dominic ChoppingNovo Nordisk agreed to pay up to $1.3 billion to license and develop Swedish pharmaceutical company Nanexa's drug delivery technology in a deal that could cut the frequency that patients need to inject its obesity and diabetes drugs.The deal covers Nanexa's PharmaShell technology…
Deutsche Bank Cuts Novo Nordisk Target Price To DKK 245 From DKK 265
Novo Nordisk: Jefferies Cuts Target Price To DKK 275 From DKK 285
The Danish drugmaker aims to deliver more than 150 billion Danish crowns ($23 billion) in pipeline sales in 2035 and reach more than 60 million patients globally by 2030, CEO Mike Doustdar said. Shares fell as much as 9% as analysts questioned the company's pricing power and dealmaking strategy ahead of looming patent
Novo Nordisk shares fell more than 2% after Morgan Stanley lowered its rating to Underweight from Equal-weight, citing longer-term semaglutide risks and potential generic competition.
Morgan Stanley cut its rating on Novo Nordisk, citing ongoing concern over semaglutide’s loss of exclusivity overhang. Shares were down more than 1% premarket.
Morgan Stanley downgraded Novo Nordisk from equal-weight to underweight and maintained a $40.00 share price target.
Iran Reignites Strait Of Hormuz Fight As US Tightens Squeeze Houthis Take Control Of Red Sea Port City Mocha Trump s Advisers Confront Possibility Iran War Lasts Through Term UK Home Prices Remain Under Pressure As Mortgage Costs Rise BoJ s Masu: Will Continue To Raise Benchmark Rate China Willing To Hold AI Talks With
LiveSquawk says German industry output unexpectedly fell most in almost a year, while Saudi Aramco’s refinery was hit in new strikes. It also cites US strikes on three Iranian ships and a planned new restricted Gulf zone.
Deutsche Bank downgraded Novo Nordisk to Sell from Hold and cut its target price to DKK 265 from DKK 290.
Boston Scientific identified a cybersecurity incident that caused global operational disruptions, including delays in processing and shipping customer orders. The company says system access remains limited and the restoration timeline is unknown; scope and financial impact are unclear.
Novo Nordisk has no plans for more major cost cuts
Novo Nordisk A/S (NYSE: NVO ) stock is trading lower on Tuesday despite the company raising its fiscal 2026 guidance. The weight loss drug maker reported second quarter sales of 78.488 billion Danish kroner, up 2% year over year (+3% at constant currency). However, the sales were down 19% from the first quarter sales o
Novo Nordisk A/S (NYSE: NVO ) stock plunged on Friday after the company announced disappointing headline results from its ZEUS Phase 3 cardiovascular outcomes trial. The data revealed that its experimental drug ziltivekimab failed to reduce the risk of major adverse cardiovascular events compared to placebo in high-ris
Morningstar cuts Novo Nordisk to Hold from Buy, keeps target price at DKK 343
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide An emerging theme in the weight loss space is the growing acknowledgement of the nee
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide An emerging theme in the weight loss space is the growing acknowledgement of the nee